Dansk | English
Sitemap
youtube_off.png
linkedin_off.png
Facebook
Portfolio

CELLADON

Was in phase II/III trial with a SERCa2a gene therapy to help heart failure patients hearts to beat without increasing the oxygen consumption (NASDAQ:CLDN)

Invested: 2010
IPO: 2013
Exit: 2014


For further information: www.celladon.net


DBV Technologies

Patches for desensitization of food allergy using epicutaneous delivery in clinical trials.

Invested: 2010
IPO 2013
Exit 2014


For further information: www.dbv-technologies.com




EPI Therapeutics

Discovery of new pharmaceuticals for the treatment of cancer within the field of epigenetics.


Invested: 2010

Sold to Gilead in 2015

 

For further information: www.gilead.com




River vision 

Develops a biologic to treat moderate to severe form of the orphan eye disorder Graves Orbitopathy, a very debilitating condition that ultimately can lead to blindness

Invested: 2012

Sold to Horizon in 2017

For further information: www.horizonpharma.com




Syntaxin LTD.

Platform with natural and modified Botulinium toxins for cell secretion inhibition.


Invested: 2010

Sold to Ipsen in 2013

 

For further information: www.ipsen.com




Vtesse

Develops VTS-270, a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint. VTS-270 is in a pivotal phase II/III clinical trial to treat patients with Niemann-Pick Disease Type C. 

Invested: 2014

Sold to Sucampo Pharmaceuticals, Inc. in 2017

For further information: www.vtessepharma.com




ziarco

Develops dermatological drugs, the lead being an H4 receptor antagonist in phase IIa for Atopic Dermatitis and soon phase IIa for Psoriasis. 

Invested: 2014

Sold to  Novartis in 2016

For further information: www.ziarcopharma.com


















logo-page.png




EPI THERA




river Vision




syntaxin-logo.gif




Vtesse_LogoFINAL_300dpi_rgb




Billede1